Patents Assigned to The University Court of the University of Dundee
-
Patent number: 11254966Abstract: The present invention relates to the production of activated biological molecules for use in profiling biological molecule interactions. The activated biological molecule may be a ubiquitin (Ub) and ubiquitin-like conjugation enzyme as well as other proteins with internal reactive cysteine residues.Type: GrantFiled: November 8, 2019Date of Patent: February 22, 2022Assignee: University Court of the University of DundeeInventors: Satpal Virdee, Mathew Stanley, Kuan-Chuan Pao
-
Patent number: 11123100Abstract: An ultrasonically actuated medical implement is used in improving medical interventions and in certain instances to the generation of image data, in particular data acquired during a medical intervention or procedure. The medical implement employs a piezoelectric element which causes reciprocation between first and second mass assemblies in order to ultrasonically actuate a probe member and improve the visibility of the probe member to imaging methods. The invention also concerns the visibility of structures in target regions to be imaged and how this may be enhanced using the medical implement of the invention.Type: GrantFiled: March 11, 2014Date of Patent: September 21, 2021Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEEInventors: Muhammad Sadiq, Sandy Cochran, Zhihong Huang, George Corner, Graeme McLeod, Patrick Carena
-
Patent number: 10829799Abstract: The present invention relates to the production of activated biological molecules for use in profiling biological molecule interactions. The activated biological molecule may be a ubiquitin (Ub) and ubiquitin-like conjugation enzyme as well as other proteins with internal reactive cysteine residues.Type: GrantFiled: September 30, 2015Date of Patent: November 10, 2020Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEEInventors: Satpal Virdee, Mathew Stanley, Kuan-Chuan Pao
-
Patent number: 10233157Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.Type: GrantFiled: May 26, 2017Date of Patent: March 19, 2019Assignees: Dana-Farber Cancer Institute, Inc., University Court of the University of DundeeInventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
-
Publication number: 20180215719Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.Type: ApplicationFiled: May 26, 2017Publication date: August 2, 2018Applicants: Dana-Farber Cancer Institute, Inc., University Court of the University of DundeeInventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
-
Patent number: 9919060Abstract: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.Type: GrantFiled: February 6, 2017Date of Patent: March 20, 2018Assignee: University Court of the University of DundeeInventors: Steven Albert Everett, Saraj Ulhaq
-
Publication number: 20170342036Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.Type: ApplicationFiled: May 26, 2017Publication date: November 30, 2017Applicants: Dana-Farber Cancer Institute, Inc., University Court of the University of DundeeInventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
-
Patent number: 9670165Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.Type: GrantFiled: March 13, 2013Date of Patent: June 6, 2017Assignees: Dana-Farber Cancer Institute, Inc., University Court of the University of DundeeInventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael Gray
-
Publication number: 20160242811Abstract: The invention relates to improving medical interventions and in certain instances to the generation of image data, in particular data acquired during a medical intervention or procedure. The invention also concerns the visibility of structures in target regions to be imaged and how this may be enhanced.Type: ApplicationFiled: March 11, 2014Publication date: August 25, 2016Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEEInventors: Muhammad Sadiq, Sandy Cochran, Zhihong Huang, George Corner, Graeme McLeod, Patrick Carena
-
Patent number: 9365508Abstract: The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar? are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases.Type: GrantFiled: June 9, 2010Date of Patent: June 14, 2016Assignees: University Court of the University of St Andrews, University Court of the University of DundeeInventors: Sonia Lain, Nicholas James Westwood, David Philip Lane
-
Patent number: 9265826Abstract: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.Type: GrantFiled: March 12, 2013Date of Patent: February 23, 2016Assignee: University Court of the University of DundeeInventors: Paul Richard Crocker, Bjoern Biedermann, David Bowen
-
Publication number: 20160000908Abstract: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.Type: ApplicationFiled: March 12, 2013Publication date: January 7, 2016Applicant: University Court of the University of DundeeInventors: Paul Richard Crocker, Bjoern Biedermann, David Bowen
-
Patent number: 9155289Abstract: Non-human animals which overexpress PPARd or which express transgenic PPARd are useful as models for inflammatory skin conditions such as psoriasis. Test substances can be screened to assess their suitability for the treatment of inflammatory skin conditions such as psoriasis. Methyl 3-({[2-(methoxy)-4-phenyl]amino}sulfonyl)-2-thiophenecarboxylate can be administered topically for the prevention or treatment of psoriasis.Type: GrantFiled: July 31, 2009Date of Patent: October 13, 2015Assignee: University Court of the University of DundeeInventors: Colin Palmer, John Foerster, Nainamalai Sitherswaran
-
Patent number: 9120765Abstract: The present invention relates to compounds which activate the p53 response, and find use in, for example, hyperproliferative diseases such as cancer treatment and potentially other diseases/conditions involving sirtuin function.Type: GrantFiled: May 3, 2013Date of Patent: September 1, 2015Assignees: University Court of the University of Dundee, University Court of the University of St. AndrewsInventors: Sonia Lain, David Phillip Lane, Michael John Raymond Stark, Anna Rose McCarthy, Jonathan James Hollick, Nicholas James Westwood
-
Patent number: 9050374Abstract: The present invention relates to a multi-functional protease inhibitor, which may be conjugated to various molecules. The present invention also relates to uses of the protease inhibitor and conjugates thereof.Type: GrantFiled: August 15, 2012Date of Patent: June 9, 2015Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEEInventors: Colin Watts, Sander Van Kasteren
-
Patent number: 8999635Abstract: The present invention relates to the identification of loss-of-function mutations in the filaggrin gene and their use in diagnosing ichthyosis vulgaris and/or susceptibility to other diseases including atopic dermatitis (eczema), asthma, psoriasis and allergies (including food allergy).Type: GrantFiled: December 15, 2006Date of Patent: April 7, 2015Assignee: University Court of The University of DundeeInventors: William Henry Irwin McLean, Frances Jane Dorothy Smith
-
Publication number: 20130302317Abstract: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.Type: ApplicationFiled: March 12, 2013Publication date: November 14, 2013Applicant: University Court of the University of DundeeInventors: Paul Richard Crocker, Bjoern Biedermann, David Bowen
-
Patent number: 8563557Abstract: The invention provides a compound according to formula (I): wherein: X is O or S; Y is O or S; each Ar and Ar? is independently a mono-, bi- or tricyclic aryl or heteroaryl group optionally substituted with one or more substituents selected from halo, alkyl, aryl, heteroaryl, hydroxyl, nitro, amino, alkoxy, alkylthio, cyano, thio, ester, acyl and amido; each R2 is independently hydrogen, halo, alkyl, aryl, heteroaryl, hydroxyl, nitro, amino, alkoxy, alkylthio, cyano and thio; and R1 is as defined herein, or a physiologically acceptable salt, solvate, ester, amide or other physiologically functional derivative thereof.Type: GrantFiled: October 2, 2009Date of Patent: October 22, 2013Assignees: University Court of the University of Dundee, University Court of the University of St AndrewsInventors: Nicholas James Westwood, Sonia Lain, Federico Medda
-
Patent number: 8512760Abstract: A process for the production of an aqueous dispersion of metal nano particles comprising palladium is provided. The process comprises the admixture of a water soluble organic polymer, a palladium salt and a first reducing agent to an aqueous liquid. The first reducing agent is a metal-containing polymer which has reducing properties or a saccharide which has reducing properties. The nano particles can include a second metal. The dispersions can be used as catalysts for electroless plating, to produce heterogeneous catalysts and in the production of anti-microbial devices and compositions.Type: GrantFiled: November 21, 2008Date of Patent: August 20, 2013Assignee: The University Court of the University of DundeeInventors: James Anthony Cairns, Roderick Allan George Gibson, Graham James Berry
-
Patent number: 8501991Abstract: The present invention relates to compounds which activate the p53 response, and find use in, for example, hyperproliferative diseases such as cancer treatment and potentially other diseases/conditions (involving sirtuin function).Type: GrantFiled: September 4, 2007Date of Patent: August 6, 2013Assignees: University Court of the University of Dundee, University Court of the University of St. AndrewsInventors: Sonia Lain, David Phillip Lane, Michael John Raymond Stark, Anna Rose McCarthy, Jonathan James Hollick, Nicholas James Westwood